Genmab — Februar 2023

[Sukkeralf]

Ny aftale fra Synaffix

[Sukkeralf]

Just a moment...

(firstwordpharma.com)

[Sukkeralf]

Med koreansk selskab

[Legolas23]

Godt fundet

[JKY_VH]

super, tak Sukkeralf

[StockBull]

Ser ud til de 50% fibonacci retracement ned til 2595 holde. Ugekort indikere bundvending. https://www.proinvestor.com/boards/107738/$/110193

[JKY_VH]

Tak SB

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[ProinvestorNEWS]

Dagens mange regnskaber: https://www.proinvestor.com/finanskalender

[bibob]

God morgen.

[bibob]

AbbVie puts bigger M&A back on the table. https://www.fiercepharma.com/pharma/abbvie-teases-future-ma-deals-worth-more-2-billion-wsj

[ProinvestorNEWS]

Shortpositioner i danske aktier d. 8. februar 2022 https://www.proinvestor.com/boards/110232

[E_L]

Kesimpta had a +7% list price change in januari. (after 5% last jan and 2% last july). that doesn't feel like they are very worried about price competition

[E_L]

from Lundbeck- The two projects that entered Proof of Concept
(phase II) testing at the end of 2021, Lu
AF82422 and Lu AG09222, are progressing well
with expected headline results within the next 12
months.

[E_L]

In September 2022, Lundbeck completed the
recruitment ahead of time for the Lu AF82422
phase II trial (AMULET) for potential new
treatment of MSA.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[deleted-user]

Med dagens afstraffelse af Chemometec og GN, imødeser jeg Genmabs 23-guide med om muligt, endnu større spænding end tidligere.

[JKY_VH]

GN er nok også påvirket af kapitaludvidelsen.